Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 15Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 11Lymphoma 11Leukemia, Myeloid, Acute 11Recurrence 10Ovarian Neoplasms 9Lymphoma, B-Cell 9Myelodysplastic Syndromes 8Pancreatic Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Lymphoma, Mantle-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Hodgkin Disease 6Hematologic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Sarcoma, Ewing 4Sarcoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Osteosarcoma 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

fludarabine 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Select Advanced Solid Tumors × Cyclophosphamide × 30 days × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡